UA103791C2 - Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу - Google Patents
Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозуInfo
- Publication number
- UA103791C2 UA103791C2 UAA201110844A UAA201110844A UA103791C2 UA 103791 C2 UA103791 C2 UA 103791C2 UA A201110844 A UAA201110844 A UA A201110844A UA A201110844 A UAA201110844 A UA A201110844A UA 103791 C2 UA103791 C2 UA 103791C2
- Authority
- UA
- Ukraine
- Prior art keywords
- methods
- tuberculosis
- compositions
- prevention
- management
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Винахід стосується способу лікування, профілактики або супроводу туберкульозу, що передбачає введення модулятора PDE4 або його фармацевтично прийнятної солі, сольвату, або стереоізомеру в комбінації з протитуберкульозним засобом.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15146709P | 2009-02-10 | 2009-02-10 | |
PCT/US2010/023533 WO2010093588A1 (en) | 2009-02-10 | 2010-02-09 | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
Publications (1)
Publication Number | Publication Date |
---|---|
UA103791C2 true UA103791C2 (uk) | 2013-11-25 |
Family
ID=42077260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201110844A UA103791C2 (uk) | 2009-02-10 | 2010-02-09 | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу |
Country Status (23)
Country | Link |
---|---|
US (1) | US20120149716A1 (uk) |
EP (2) | EP2395995A1 (uk) |
JP (2) | JP2012517441A (uk) |
KR (1) | KR20110116049A (uk) |
CN (1) | CN102387798A (uk) |
AP (1) | AP3437A (uk) |
AU (1) | AU2010213936B2 (uk) |
BR (1) | BRPI1007500A2 (uk) |
CA (1) | CA2750123A1 (uk) |
CO (1) | CO6410289A2 (uk) |
CR (1) | CR20110411A (uk) |
EA (1) | EA201171035A1 (uk) |
EC (1) | ECSP11011295A (uk) |
HK (1) | HK1205681A1 (uk) |
IL (1) | IL214176A (uk) |
MX (1) | MX2011008132A (uk) |
MY (1) | MY160002A (uk) |
NI (1) | NI201100154A (uk) |
NZ (1) | NZ594193A (uk) |
PE (2) | PE20151143A1 (uk) |
SG (2) | SG173149A1 (uk) |
UA (1) | UA103791C2 (uk) |
WO (1) | WO2010093588A1 (uk) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6143675B2 (ja) | 2010-12-16 | 2017-06-07 | セルジーン コーポレイション | 難溶性薬物の制御放出経口剤形及びその使用 |
CA2848493A1 (en) | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide |
BR112014015923B1 (pt) | 2011-12-27 | 2022-02-01 | Amgen (Europe) GmbH | Comprimidos revestidos de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4 - acetilaminoisoindolina-1,3-diona |
WO2013119607A2 (en) * | 2012-02-08 | 2013-08-15 | Celgene Corporation | Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
WO2017030892A1 (en) | 2015-08-14 | 2017-02-23 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
DE102018201827A1 (de) * | 2017-02-28 | 2018-08-30 | Aktiebolaget Skf | Wälzlager |
CN112220785B (zh) * | 2020-09-22 | 2021-12-31 | 北京鑫开元医药科技有限公司 | 一种pde4抑制剂药物组合物及其制备方法与用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
IT1276040B1 (it) * | 1993-07-27 | 1997-10-24 | Angelini Francesco Ist Ricerca | Uso della benzidamina nel trattamento di stati patologici causati dal tnf |
CN1143363A (zh) * | 1994-03-09 | 1997-02-19 | 辉瑞大药厂 | 作为tnf释放抑制剂的异噁唑啉化合物 |
US5610198A (en) * | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
KR100539030B1 (ko) | 1996-08-12 | 2005-12-27 | 셀진 코포레이션 | 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법 |
ES2196592T3 (es) | 1997-07-31 | 2003-12-16 | Celgene Corp | Acidos alcanohidroxamicos sustituidos y metodo para reducir el nivel de tnf-alfa. |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US8030343B2 (en) * | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
NZ518216A (en) * | 2000-08-09 | 2004-11-26 | Panacea Biotec Ltd | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
CA2505131A1 (en) * | 2002-11-06 | 2004-05-27 | Celgene Corporation | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
BR0316256A (pt) | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
ZA200505308B (en) | 2002-12-30 | 2006-10-25 | Celgene Corp | Fluoroalkoxy-substituted 1, 3-Dihydro-Isoindolyl compounds and their pharmaceutical uses |
MXPA05009434A (es) | 2003-03-05 | 2005-11-23 | Celgene Corp | Compuestos de difeniletileno y usos de los mismos. |
JP4713465B2 (ja) | 2003-03-12 | 2011-06-29 | セルジーン コーポレイション | 7−アミド−イソインドリル化合物およびその薬学的使用 |
WO2004080422A2 (en) | 2003-03-12 | 2004-09-23 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
US7244259B2 (en) | 2003-10-31 | 2007-07-17 | Ethicon, Inc. | Guide for surgical device for the treatment of urinary incontinence |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
AU2005316593A1 (en) * | 2004-12-13 | 2006-06-22 | Celgene Corporation | Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation |
TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
-
2010
- 2010-02-09 JP JP2011549315A patent/JP2012517441A/ja active Pending
- 2010-02-09 AP AP2011005849A patent/AP3437A/xx active
- 2010-02-09 EP EP10704460A patent/EP2395995A1/en not_active Withdrawn
- 2010-02-09 MY MYPI2011003673A patent/MY160002A/en unknown
- 2010-02-09 SG SG2011054129A patent/SG173149A1/en unknown
- 2010-02-09 UA UAA201110844A patent/UA103791C2/uk unknown
- 2010-02-09 MX MX2011008132A patent/MX2011008132A/es active IP Right Grant
- 2010-02-09 WO PCT/US2010/023533 patent/WO2010093588A1/en active Application Filing
- 2010-02-09 US US13/148,659 patent/US20120149716A1/en not_active Abandoned
- 2010-02-09 CA CA2750123A patent/CA2750123A1/en not_active Abandoned
- 2010-02-09 PE PE2015000636A patent/PE20151143A1/es not_active Application Discontinuation
- 2010-02-09 EP EP14170043.5A patent/EP2818164A1/en not_active Withdrawn
- 2010-02-09 NZ NZ594193A patent/NZ594193A/xx not_active IP Right Cessation
- 2010-02-09 PE PE2011001445A patent/PE20120580A1/es not_active Application Discontinuation
- 2010-02-09 AU AU2010213936A patent/AU2010213936B2/en not_active Ceased
- 2010-02-09 SG SG10201402158VA patent/SG10201402158VA/en unknown
- 2010-02-09 KR KR1020117021146A patent/KR20110116049A/ko not_active Application Discontinuation
- 2010-02-09 CN CN2010800159215A patent/CN102387798A/zh active Pending
- 2010-02-09 EA EA201171035A patent/EA201171035A1/ru unknown
- 2010-02-09 BR BRPI1007500A patent/BRPI1007500A2/pt not_active IP Right Cessation
-
2011
- 2011-07-19 IL IL214176A patent/IL214176A/en not_active IP Right Cessation
- 2011-07-29 CR CR20110411A patent/CR20110411A/es unknown
- 2011-08-09 NI NI201100154A patent/NI201100154A/es unknown
- 2011-08-21 EC EC2011011295A patent/ECSP11011295A/es unknown
- 2011-09-09 CO CO11116668A patent/CO6410289A2/es not_active Application Discontinuation
-
2015
- 2015-04-13 JP JP2015081559A patent/JP2015164928A/ja active Pending
- 2015-06-30 HK HK15106201.5A patent/HK1205681A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SG173149A1 (en) | 2011-08-29 |
IL214176A (en) | 2016-09-29 |
CO6410289A2 (es) | 2012-03-30 |
EP2395995A1 (en) | 2011-12-21 |
PE20120580A1 (es) | 2012-05-23 |
JP2012517441A (ja) | 2012-08-02 |
KR20110116049A (ko) | 2011-10-24 |
CR20110411A (es) | 2012-01-06 |
EP2818164A1 (en) | 2014-12-31 |
NZ594193A (en) | 2013-09-27 |
CN102387798A (zh) | 2012-03-21 |
AP2011005849A0 (en) | 2011-08-31 |
BRPI1007500A2 (pt) | 2016-02-16 |
AU2010213936B2 (en) | 2014-07-31 |
ECSP11011295A (es) | 2011-09-30 |
SG10201402158VA (en) | 2014-07-30 |
AU2010213936A1 (en) | 2011-08-11 |
PE20151143A1 (es) | 2015-08-07 |
NI201100154A (es) | 2012-01-24 |
EA201171035A1 (ru) | 2012-02-28 |
WO2010093588A1 (en) | 2010-08-19 |
US20120149716A1 (en) | 2012-06-14 |
MY160002A (en) | 2017-02-15 |
CA2750123A1 (en) | 2010-08-19 |
JP2015164928A (ja) | 2015-09-17 |
IL214176A0 (en) | 2011-08-31 |
AP3437A (en) | 2015-10-31 |
MX2011008132A (es) | 2011-09-06 |
HK1205681A1 (en) | 2015-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA103791C2 (uk) | Композиція, що включає модулятор pde4, і спосіб її застосування для лікування, профілактики або супроводу туберкульозу | |
PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
WO2012027065A3 (en) | Combination therapy for treatment of disease | |
WO2005044178A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
WO2005105088A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension | |
MX2015009773A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
MXPA05004778A (es) | Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas. | |
WO2015097621A3 (en) | Pharmaceutical combinations | |
MX2015009785A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
WO2005097125A3 (en) | Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease | |
MX2015009778A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
PH12014501495B1 (en) | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione | |
AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
WO2006063164A3 (en) | Compositions and methods for treating neuroendocrine tumors | |
MX2007005040A (es) | Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central. | |
WO2005039497A3 (en) | Methods and compositions comprising thalidomide for treatment of fibromyalgia | |
WO2004041190A3 (en) | Composition for the treatment of macular degenration | |
TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. |